LAVA Therapeutics NV (NASDAQ: LVTX) Not A Good Play Anymore?

LAVA Therapeutics NV (LVTX) concluded trading on Thursday at a closing price of $3.33, with 0.49 million shares of worth about $1.63 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 114.96% during that period and on March 28, 2024 the price saw a loss of about -14.83%. Currently the company’s common shares owned by public are about 26.29M shares, out of which, 14.12M shares are available for trading.

Stock saw a price change of 2.46% in past 5 days and over the past one month there was a price change of 54.17%. Year-to-date (YTD), LVTX shares are showing a performance of 110.76% which increased to 105.56% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.13 but also hit the highest price of $6.47 during that period. The average intraday trading volume for LAVA Therapeutics NV shares is 1.79 million. The stock is currently trading 12.65% above its 20-day simple moving average (SMA20), while that difference is up 46.71% for SMA50 and it goes to 83.40% higher than SMA200.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


LAVA Therapeutics NV (NASDAQ: LVTX) currently have 26.29M outstanding shares and institutions hold larger chunk of about 15.05% of that.

The stock has a current market capitalization of $87.55M and its 3Y-monthly beta is at 0.67. It has posted earnings per share of -$1.59 in the same period. It has Quick Ratio of 6.62 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LVTX, volatility over the week remained 14.99% while standing at 30.06% over the month.

Analysts are in expectations that LAVA Therapeutics NV (LVTX) stock would likely to be making an EPS of -$0.12 in the current quarter, while forecast for next quarter EPS is -$0.43 and it is -$2.19 for next year. For the current quarter EPS, analysts have given the company a lowest target -$0.17 which is -$0.08 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -$0.53 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 4.94% while it is estimated to decrease by -37.86% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by H.C. Wainwright on October 25, 2022 offering a Buy rating for the stock and assigned a target price of $9 to it. Coverage by SVB Leerink stated LAVA Therapeutics NV (LVTX) stock as an Outperform in their note to investors on April 19, 2021, suggesting a price target of $26 for the stock. On April 19, 2021, JP Morgan Initiated their recommendations, while on April 19, 2021, Jefferies Initiated their ratings for the stock with a price target of $23.

Most Popular

Related Posts